Oxford BioMedica is recruiting artificial intelligence to improve the productivity, purity, and manufacturing of viral vectors used in its gene therapies, which target diseases such as cancer and age-related macular degeneration. The company has signed a two-year development collaboration with Microsoft to access its artificial intelligence platform, called Station B.
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
View Patent Forecast®
Top Corporations
News and Insights
Data Visualization
Artificial intelligence and human health don’t stop with our general diagnostics, cardiology, neurology, and activity sectors. This sector covers AI/ML-centric advancements in auditory, dental, GI/hepatic, circulatory, immune, musculoskeletal, ocular, reproductive, respiratory, dermatological, urinary, rectal, and spectrometry related biotech.
